Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study
•We evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC)•We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 to asse...
Gespeichert in:
| Veröffentlicht in: | Urologic oncology 2022-02, Vol.40 (2), p.64.e1-64.e8 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 64.e8 |
|---|---|
| container_issue | 2 |
| container_start_page | 64.e1 |
| container_title | Urologic oncology |
| container_volume | 40 |
| creator | Sasaki, Daichi Hatakeyama, Shingo Kawaguchi, Hideo Hatayama, Yoshiomi Ishibashi, Yusuke Kusaka, Ayumu Noro, Daisuke Tanaka, Toshikazu Ito, Hiroyuki Okuyama, Yoshiharu Okamoto, Teppei Yamamoto, Hayato Yoneyama, Takahiro Hashimoto, Yasuhiro Aoki, Masahiko Ohyama, Chikara |
| description | •We evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC)•We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the factors associated with Ra223 incompletion (fewer than 6 cycles).•We found unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, and Ra223 incompletion were significantly associated with poor overall survival.•Unfavorable factors (EOD 3–4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion.•Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival.
To evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC).
We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 between August 2016 and August 2021. The primary purpose of the study was to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the secondary purpose was to investigate factors associated with Ra223 incompletion (fewer than 6 cycles) and overall survival.
The median age of the patients was 72 years. The median number of Ra223 administrations was 6 (interquartile range, 5–6), and the median Ra223 completion rate was 75%. The median time from mCRPC diagnosis to Ra223 administration was 17 months, and the median number of prior treatments was 2. Multivariable analysis indicated that unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, extension of bone metastasis score 3 to 4, and Ra223 incompletion were significantly associated with poor overall survival. In addition, EOD 3 to 4 and 3 or more prior CRPC treatments were significantly associated with Ra223 incompletion.
Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival. Unfavorable factors (EOD 3–4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion.
[Display omitted] |
| doi_str_mv | 10.1016/j.urolonc.2021.11.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2616278476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143921005019</els_id><sourcerecordid>2616278476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-78d86f80dfcb0c1df2da7d2072102ebf3642421e34318e640de6006cc46200b63</originalsourceid><addsrcrecordid>eNqFkc-OFCEQxjtG4_7RR9Bw9NIjRTPAeDGbzeqabOJFz4SBQpnQTQv06ryXDyidGb16opL6VX0f9XXdK6AboCDeHjZLTjFNdsMogw3AhtLtk-4SlBx6xnfiaaupVD3wYXfRXZVyoBS4AnjeXQx8Jwe1lZfd7zvv0dZCkicl_Ort0UYkNo1zxBrSRMzkCJocA2ayFFy5bFxYxp6xgdTvmM18JA2cc_o2pRIK8SmTEasp1dRgiW1FNuuyPmPrVzPVlV7bTcpMFvM7ckMymtj_TDk6Mi6xTeJUm2jG2ti5mQyPSEpd3PFF98ybWPDl-b3uvn64-3J73z98_vjp9uaht1yq2kvllPCKOm_31ILzzBnpGJUMKMO9HwRnnAEOfACFglOHglJhLReM0r0Yrrs3p73N7Y8FS9VjKBZjNBOmpWgmQDCpuFzR7Qm1zWzJ6PWcw2jyUQPVa2D6oM-B6TUwDaBbYG3u9Vli2Y_o_k39TagB708Ato8-thR0sQHbzVzI7SbapfAfiT9vdq55</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616278476</pqid></control><display><type>article</type><title>Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sasaki, Daichi ; Hatakeyama, Shingo ; Kawaguchi, Hideo ; Hatayama, Yoshiomi ; Ishibashi, Yusuke ; Kusaka, Ayumu ; Noro, Daisuke ; Tanaka, Toshikazu ; Ito, Hiroyuki ; Okuyama, Yoshiharu ; Okamoto, Teppei ; Yamamoto, Hayato ; Yoneyama, Takahiro ; Hashimoto, Yasuhiro ; Aoki, Masahiko ; Ohyama, Chikara</creator><creatorcontrib>Sasaki, Daichi ; Hatakeyama, Shingo ; Kawaguchi, Hideo ; Hatayama, Yoshiomi ; Ishibashi, Yusuke ; Kusaka, Ayumu ; Noro, Daisuke ; Tanaka, Toshikazu ; Ito, Hiroyuki ; Okuyama, Yoshiharu ; Okamoto, Teppei ; Yamamoto, Hayato ; Yoneyama, Takahiro ; Hashimoto, Yasuhiro ; Aoki, Masahiko ; Ohyama, Chikara</creatorcontrib><description>•We evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC)•We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the factors associated with Ra223 incompletion (fewer than 6 cycles).•We found unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, and Ra223 incompletion were significantly associated with poor overall survival.•Unfavorable factors (EOD 3–4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion.•Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival.
To evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC).
We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 between August 2016 and August 2021. The primary purpose of the study was to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the secondary purpose was to investigate factors associated with Ra223 incompletion (fewer than 6 cycles) and overall survival.
The median age of the patients was 72 years. The median number of Ra223 administrations was 6 (interquartile range, 5–6), and the median Ra223 completion rate was 75%. The median time from mCRPC diagnosis to Ra223 administration was 17 months, and the median number of prior treatments was 2. Multivariable analysis indicated that unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, extension of bone metastasis score 3 to 4, and Ra223 incompletion were significantly associated with poor overall survival. In addition, EOD 3 to 4 and 3 or more prior CRPC treatments were significantly associated with Ra223 incompletion.
Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival. Unfavorable factors (EOD 3–4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion.
[Display omitted]</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2021.11.005</identifier><identifier>PMID: 34973857</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Humans ; Male ; Metastatic castration-resistant prostate cancer ; Prognosis ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Radium - pharmacology ; Radium - therapeutic use ; Radium-223 ; Retrospective Studies ; Six cycles ; Skeletal-related events ; Survival</subject><ispartof>Urologic oncology, 2022-02, Vol.40 (2), p.64.e1-64.e8</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-78d86f80dfcb0c1df2da7d2072102ebf3642421e34318e640de6006cc46200b63</citedby><cites>FETCH-LOGICAL-c478t-78d86f80dfcb0c1df2da7d2072102ebf3642421e34318e640de6006cc46200b63</cites><orcidid>0000-0002-7104-0945 ; 0000-0002-3760-919X ; 0000-0002-8187-7212 ; 0000-0002-0026-4079 ; 0000-0002-9450-0027</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urolonc.2021.11.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34973857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sasaki, Daichi</creatorcontrib><creatorcontrib>Hatakeyama, Shingo</creatorcontrib><creatorcontrib>Kawaguchi, Hideo</creatorcontrib><creatorcontrib>Hatayama, Yoshiomi</creatorcontrib><creatorcontrib>Ishibashi, Yusuke</creatorcontrib><creatorcontrib>Kusaka, Ayumu</creatorcontrib><creatorcontrib>Noro, Daisuke</creatorcontrib><creatorcontrib>Tanaka, Toshikazu</creatorcontrib><creatorcontrib>Ito, Hiroyuki</creatorcontrib><creatorcontrib>Okuyama, Yoshiharu</creatorcontrib><creatorcontrib>Okamoto, Teppei</creatorcontrib><creatorcontrib>Yamamoto, Hayato</creatorcontrib><creatorcontrib>Yoneyama, Takahiro</creatorcontrib><creatorcontrib>Hashimoto, Yasuhiro</creatorcontrib><creatorcontrib>Aoki, Masahiko</creatorcontrib><creatorcontrib>Ohyama, Chikara</creatorcontrib><title>Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>•We evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC)•We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the factors associated with Ra223 incompletion (fewer than 6 cycles).•We found unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, and Ra223 incompletion were significantly associated with poor overall survival.•Unfavorable factors (EOD 3–4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion.•Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival.
To evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC).
We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 between August 2016 and August 2021. The primary purpose of the study was to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the secondary purpose was to investigate factors associated with Ra223 incompletion (fewer than 6 cycles) and overall survival.
The median age of the patients was 72 years. The median number of Ra223 administrations was 6 (interquartile range, 5–6), and the median Ra223 completion rate was 75%. The median time from mCRPC diagnosis to Ra223 administration was 17 months, and the median number of prior treatments was 2. Multivariable analysis indicated that unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, extension of bone metastasis score 3 to 4, and Ra223 incompletion were significantly associated with poor overall survival. In addition, EOD 3 to 4 and 3 or more prior CRPC treatments were significantly associated with Ra223 incompletion.
Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival. Unfavorable factors (EOD 3–4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion.
[Display omitted]</description><subject>Aged</subject><subject>Humans</subject><subject>Male</subject><subject>Metastatic castration-resistant prostate cancer</subject><subject>Prognosis</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Radium - pharmacology</subject><subject>Radium - therapeutic use</subject><subject>Radium-223</subject><subject>Retrospective Studies</subject><subject>Six cycles</subject><subject>Skeletal-related events</subject><subject>Survival</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc-OFCEQxjtG4_7RR9Bw9NIjRTPAeDGbzeqabOJFz4SBQpnQTQv06ryXDyidGb16opL6VX0f9XXdK6AboCDeHjZLTjFNdsMogw3AhtLtk-4SlBx6xnfiaaupVD3wYXfRXZVyoBS4AnjeXQx8Jwe1lZfd7zvv0dZCkicl_Ort0UYkNo1zxBrSRMzkCJocA2ayFFy5bFxYxp6xgdTvmM18JA2cc_o2pRIK8SmTEasp1dRgiW1FNuuyPmPrVzPVlV7bTcpMFvM7ckMymtj_TDk6Mi6xTeJUm2jG2ti5mQyPSEpd3PFF98ybWPDl-b3uvn64-3J73z98_vjp9uaht1yq2kvllPCKOm_31ILzzBnpGJUMKMO9HwRnnAEOfACFglOHglJhLReM0r0Yrrs3p73N7Y8FS9VjKBZjNBOmpWgmQDCpuFzR7Qm1zWzJ6PWcw2jyUQPVa2D6oM-B6TUwDaBbYG3u9Vli2Y_o_k39TagB708Ato8-thR0sQHbzVzI7SbapfAfiT9vdq55</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Sasaki, Daichi</creator><creator>Hatakeyama, Shingo</creator><creator>Kawaguchi, Hideo</creator><creator>Hatayama, Yoshiomi</creator><creator>Ishibashi, Yusuke</creator><creator>Kusaka, Ayumu</creator><creator>Noro, Daisuke</creator><creator>Tanaka, Toshikazu</creator><creator>Ito, Hiroyuki</creator><creator>Okuyama, Yoshiharu</creator><creator>Okamoto, Teppei</creator><creator>Yamamoto, Hayato</creator><creator>Yoneyama, Takahiro</creator><creator>Hashimoto, Yasuhiro</creator><creator>Aoki, Masahiko</creator><creator>Ohyama, Chikara</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7104-0945</orcidid><orcidid>https://orcid.org/0000-0002-3760-919X</orcidid><orcidid>https://orcid.org/0000-0002-8187-7212</orcidid><orcidid>https://orcid.org/0000-0002-0026-4079</orcidid><orcidid>https://orcid.org/0000-0002-9450-0027</orcidid></search><sort><creationdate>202202</creationdate><title>Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study</title><author>Sasaki, Daichi ; Hatakeyama, Shingo ; Kawaguchi, Hideo ; Hatayama, Yoshiomi ; Ishibashi, Yusuke ; Kusaka, Ayumu ; Noro, Daisuke ; Tanaka, Toshikazu ; Ito, Hiroyuki ; Okuyama, Yoshiharu ; Okamoto, Teppei ; Yamamoto, Hayato ; Yoneyama, Takahiro ; Hashimoto, Yasuhiro ; Aoki, Masahiko ; Ohyama, Chikara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-78d86f80dfcb0c1df2da7d2072102ebf3642421e34318e640de6006cc46200b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Humans</topic><topic>Male</topic><topic>Metastatic castration-resistant prostate cancer</topic><topic>Prognosis</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Radium - pharmacology</topic><topic>Radium - therapeutic use</topic><topic>Radium-223</topic><topic>Retrospective Studies</topic><topic>Six cycles</topic><topic>Skeletal-related events</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sasaki, Daichi</creatorcontrib><creatorcontrib>Hatakeyama, Shingo</creatorcontrib><creatorcontrib>Kawaguchi, Hideo</creatorcontrib><creatorcontrib>Hatayama, Yoshiomi</creatorcontrib><creatorcontrib>Ishibashi, Yusuke</creatorcontrib><creatorcontrib>Kusaka, Ayumu</creatorcontrib><creatorcontrib>Noro, Daisuke</creatorcontrib><creatorcontrib>Tanaka, Toshikazu</creatorcontrib><creatorcontrib>Ito, Hiroyuki</creatorcontrib><creatorcontrib>Okuyama, Yoshiharu</creatorcontrib><creatorcontrib>Okamoto, Teppei</creatorcontrib><creatorcontrib>Yamamoto, Hayato</creatorcontrib><creatorcontrib>Yoneyama, Takahiro</creatorcontrib><creatorcontrib>Hashimoto, Yasuhiro</creatorcontrib><creatorcontrib>Aoki, Masahiko</creatorcontrib><creatorcontrib>Ohyama, Chikara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sasaki, Daichi</au><au>Hatakeyama, Shingo</au><au>Kawaguchi, Hideo</au><au>Hatayama, Yoshiomi</au><au>Ishibashi, Yusuke</au><au>Kusaka, Ayumu</au><au>Noro, Daisuke</au><au>Tanaka, Toshikazu</au><au>Ito, Hiroyuki</au><au>Okuyama, Yoshiharu</au><au>Okamoto, Teppei</au><au>Yamamoto, Hayato</au><au>Yoneyama, Takahiro</au><au>Hashimoto, Yasuhiro</au><au>Aoki, Masahiko</au><au>Ohyama, Chikara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2022-02</date><risdate>2022</risdate><volume>40</volume><issue>2</issue><spage>64.e1</spage><epage>64.e8</epage><pages>64.e1-64.e8</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>•We evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC)•We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the factors associated with Ra223 incompletion (fewer than 6 cycles).•We found unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, and Ra223 incompletion were significantly associated with poor overall survival.•Unfavorable factors (EOD 3–4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion.•Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival.
To evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC).
We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 between August 2016 and August 2021. The primary purpose of the study was to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the secondary purpose was to investigate factors associated with Ra223 incompletion (fewer than 6 cycles) and overall survival.
The median age of the patients was 72 years. The median number of Ra223 administrations was 6 (interquartile range, 5–6), and the median Ra223 completion rate was 75%. The median time from mCRPC diagnosis to Ra223 administration was 17 months, and the median number of prior treatments was 2. Multivariable analysis indicated that unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, extension of bone metastasis score 3 to 4, and Ra223 incompletion were significantly associated with poor overall survival. In addition, EOD 3 to 4 and 3 or more prior CRPC treatments were significantly associated with Ra223 incompletion.
Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival. Unfavorable factors (EOD 3–4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34973857</pmid><doi>10.1016/j.urolonc.2021.11.005</doi><orcidid>https://orcid.org/0000-0002-7104-0945</orcidid><orcidid>https://orcid.org/0000-0002-3760-919X</orcidid><orcidid>https://orcid.org/0000-0002-8187-7212</orcidid><orcidid>https://orcid.org/0000-0002-0026-4079</orcidid><orcidid>https://orcid.org/0000-0002-9450-0027</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1439 |
| ispartof | Urologic oncology, 2022-02, Vol.40 (2), p.64.e1-64.e8 |
| issn | 1078-1439 1873-2496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2616278476 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Aged Humans Male Metastatic castration-resistant prostate cancer Prognosis Prostatic Neoplasms, Castration-Resistant - drug therapy Radium - pharmacology Radium - therapeutic use Radium-223 Retrospective Studies Six cycles Skeletal-related events Survival |
| title | Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A07%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20six-cycle%20completion%20and%20earlier%20use%20of%20radium-223%20therapy%20on%20prognosis%20for%20metastatic%20castration-resistant%20prostate%20cancer:%20A%20real-world%20multicenter%20retrospective%20study&rft.jtitle=Urologic%20oncology&rft.au=Sasaki,%20Daichi&rft.date=2022-02&rft.volume=40&rft.issue=2&rft.spage=64.e1&rft.epage=64.e8&rft.pages=64.e1-64.e8&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2021.11.005&rft_dat=%3Cproquest_cross%3E2616278476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616278476&rft_id=info:pmid/34973857&rft_els_id=S1078143921005019&rfr_iscdi=true |